Gary Solomon
Rheumatology · New York, NYNPI 1134193451
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $47,880 of the $63,908 with a category attached, or 74.9%. AbbVie accounts for 77.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2024 at $20,745 and has fallen 65.4% since, to $7,187 in 2025. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $332.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$50K
- Amgen$8K
- Johnson & Johnson$2K
- Pfizer$2K
- Novartis$825
- UCB, Inc.$574
- plus $622 from 3 others
What the payments were for
- Consulting fees$8,66014%
- Speaking & faculty fees$47,88075%
- Travel & lodging$1,6313%
- Food & beverage$5,6919%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 91 | $49,627 |
| Amgen | 14 | $7,679 |
| Johnson & Johnson | 4 | $2,437 |
| Pfizer | 13 | $2,146 |
| Novartis | 48 | $825 |
| UCB, Inc. | 7 | $574 |
| Lilly USA, LLC | 10 | $372 |
| Bristol Myers Squibb | 4 | $141 |
| Regeneron Healthcare Solutions, Inc. | 1 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,908 in reported general payments places this provider in the 90th percentile of 541 rheumatology providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xeljanz XrTofacitinib Citrate | 149 | $929,044 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 80 | $782,397 |
| Enbrel SureclickEtanercept | 78 | $701,529 |
| RinvoqUpadacitinib | 79 | $622,384 |
| Humira(Cf) PenAdalimumab | 39 | $352,396 |
| Cimzia (2 Pack)Certolizumab Pegol | 19 | $316,261 |
| EnbrelEtanercept | 22 | $234,727 |
| ActemraTocilizumab | 17 | $125,217 |
| MethotrexateMethotrexate Sodium | 307 | $9,426 |
| Hydroxychloroquine Sulfate | 96 | $4,966 |
| Prednisone | 275 | $3,012 |
| ValacyclovirValacyclovir Hcl | 22 | $1,748 |
| Leucovorin Calcium | 35 | $1,401 |
| Celecoxib | 40 | $1,148 |
| Levothyroxine Sodium | 74 | $1,092 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $49,627 | $622,38479 claims |
| UCB, Inc.Cimzia (2 Pack) | $574 | $316,26119 claims |
| AmgenEnbrel | $7,679 | $234,72722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 541 rheumatology providers in New York.
Other rheumatology in New York
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Olga PetrynaNew York$509K
- Danielle PeterselNew York$461K
- Jose ScherNew York$446K
- Jason FallerNew York$357K
- Lindsay LallyNew York$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.